Table 2 |
|||||||||
|
Clinical parameters and HPV characteristics of 6 plasma HPV DNA positive CC patients |
|||||||||
|
Patient |
Age |
Stagea |
Pathology |
Tumor |
Response to |
Time |
Metastatic |
HPV |
Relative |
|
Code |
Type |
Size |
Radiotherapy |
Recur |
Organ |
type |
amount of |
||
|
(cm) |
(month)b |
E6:ZP3 |
|||||||
|
PCRf |
|||||||||
|
|
|||||||||
|
4 |
39 |
IIB |
Adenomatous |
7 |
Partial |
18 |
0.02 |
||
|
148 |
65 |
IIB |
Squamous |
3 |
Complete |
8 |
Pleura, |
18 |
0.04 |
|
Peritoneumc |
|||||||||
|
183 |
27 |
IIB |
Squamous |
6 |
Partial |
11 |
Bone c |
18 |
0.05 |
|
106 |
51 |
IVB |
Squamous |
>4 |
Liver, Pleurad |
18 |
0.14 |
||
|
161 |
34 |
Re |
Squamous |
7 |
Umbillicus d |
16 |
0.19 |
||
|
59 |
46 |
Re |
Squamous |
5 |
Liver, Lung d |
16 |
0.05 |
||
|
|
|||||||||
|
a Stage at the time of blood examination; bTime for recurrence after complete treatment; c Metastasis at time of recurrence; d Metastasis at time of plasma DNA analysis; e R, recurrence; f Average amount from two experiments |
|||||||||
|
Pornthanakasem et al. BMC Cancer 2001 1:2 doi:10.1186/1471-2407-1-2 |
|||||||||